{"gene":"CSNK2A1","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1988,"finding":"The CKA1 gene of S. cerevisiae encodes the 42 kDa alpha catalytic subunit of casein kinase II, which is 67% identical to the Drosophila CK2α. Null mutations in CKA1 alone are phenotypically wild type, indicating functional redundancy with the alpha' subunit encoded by CKA2.","method":"Gene isolation, sequencing, gene replacement/disruption","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — direct gene disruption with defined phenotypic readout, sequence-level characterization","pmids":["3062376"],"is_preprint":false},{"year":1990,"finding":"CK2 catalytic activity (encoded by CKA1 and CKA2) is essential for viability in S. cerevisiae; simultaneous disruption of both catalytic subunit genes is lethal. Cells depleted of CK2 activity arrest with increased cell size and a pseudomycelial morphology. Yeast lacking both endogenous catalytic subunits are rescued by expression of Drosophila CK2α alone (free monomeric catalytic subunit) or α+β, demonstrating evolutionary conservation of function.","method":"Double gene disruption, complementation with Drosophila subunits, genetic rescue assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution/rescue genetics with defined lethal phenotype, replicated across constructs","pmids":["2196445"],"is_preprint":false},{"year":1992,"finding":"The free monomeric CK2α catalytic subunit is not toxic in vivo and is sufficient to rescue lethality of cka1/cka2 double disruption. CK2 purified from rescued strains shows that free alpha monomer is catalytically active; overexpression of total CK2 activity 6–18 fold has no overt phenotypic consequence.","method":"Purification and biochemical characterization of CK2 from genetically rescued yeast strains, in vitro kinase assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, purification, and in vitro activity assays","pmids":["1527008"],"is_preprint":false},{"year":1994,"finding":"The human CSNK2A1 gene is located on chromosome 20p13. The gene contains tandemly arranged Alu repeats within introns and consists of at least 8 exons (bases 102–824 of coding region characterized). Exon/intron boundaries conform to the gt/ag rule.","method":"Genomic cloning, sequencing, FISH chromosomal localization","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromosomal mapping and structural characterization","pmids":["8188256"],"is_preprint":false},{"year":1995,"finding":"CK2 is a ubiquitous eukaryotic serine/threonine kinase that phosphorylates more than 100 substrates involved in cell division and signal transduction. The α subunit is the catalytic subunit and the β subunit is regulatory; they form an α2β2 tetrameric holoenzyme. CK2 activity is constitutive and is present in both nucleus and cytoplasm.","method":"Biochemical characterization, review of in vitro kinase assays across multiple studies","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 — extensive biochemical evidence compiled across many studies, widely replicated","pmids":["7896000"],"is_preprint":false},{"year":1998,"finding":"The complete human CSNK2A1 gene spans 70 kb and consists of 13 exons. The promoter lacks a TATA box, contains a CpG island and GC boxes, characteristic of a housekeeping gene. Promoter activity was confirmed by reporter gene assay within the region from position −256 to +144. Two transcription start sites were identified by primer extension.","method":"Genomic cloning, sequencing, reporter gene assay, primer extension","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct experimental characterization of promoter activity","pmids":["9503018"],"is_preprint":false},{"year":1998,"finding":"Temperature-sensitive mutations in yeast CKA1 reveal a specific role for CK2α in maintenance of cell polarity. cka1(ts) strains arrest with nonpolarized actin cytoskeleton, delocalized chitin deposition, and multinucleate cell bodies, demonstrating functional specialization of CKA1 versus CKA2 catalytic subunits.","method":"Temperature-sensitive allele generation, fluorescence microscopy, cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — conditional allele with multiple orthogonal phenotypic readouts (actin, chitin, nuclear content)","pmids":["9488724"],"is_preprint":false},{"year":2000,"finding":"CK2 phosphorylates α-synuclein constitutively at serine 129 in vivo. This phosphorylation site was mapped by site-directed mutagenesis and confirmed by in vitro kinase assay and two-dimensional phosphopeptide mapping. Inhibition of CK2 in vivo reduces phosphorylation at Ser129.","method":"Site-directed mutagenesis, in vitro kinase assay, 2D phosphopeptide mapping, CK2 inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with mutagenesis and in vivo pharmacological validation","pmids":["10617630"],"is_preprint":false},{"year":2001,"finding":"CK2 phosphorylates the tumor suppressor PTEN at a cluster of Ser/Thr residues in its C-terminal regulatory domain in a constitutive manner. Phosphorylation-defective PTEN mutants showed decreased stability and accelerated proteasomal degradation, indicating that CK2-mediated phosphorylation stabilizes PTEN against proteasomal degradation.","method":"In vitro kinase assay, site-directed mutagenesis, proteasome inhibitor studies, protein stability assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with mutagenesis and functional stability readout","pmids":["11035045"],"is_preprint":false},{"year":2011,"finding":"CK2 directly phosphorylates p62/SQSTM1 at serine 403 within its ubiquitin-associated (UBA) domain. This phosphorylation increases the affinity of UBA for polyubiquitin chains, enhancing autophagic clearance of polyubiquitinated proteins. CK2 overexpression reduces formation of polyglutamine-expanded huntingtin inclusion bodies in a p62-dependent manner.","method":"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, autophagy flux assays, cellular inclusion body formation assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro phosphorylation with mutagenesis and multiple functional readouts","pmids":["22017874"],"is_preprint":false},{"year":2011,"finding":"Yeast Cka2 kinase phosphorylates C-terminal serines of the E2 ubiquitin-conjugating enzyme Cdc34 (tmCdc34 mutant), and this phosphorylation prevents the synthesis of free polyubiquitin chains, likely by promoting their attachment to substrate. This reveals a regulatory role for CK2α in the ubiquitin-proteasome pathway.","method":"In vitro kinase assay, polyubiquitination assay, genetic epistasis with Ubp14","journal":"Cell division","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro kinase assay with defined functional consequence, single study","pmids":["21453497"],"is_preprint":false},{"year":2015,"finding":"Yeast CKA2 regulates nitric oxide (NO) accumulation by controlling NOS-like activity, and thereby functions in H2O2-induced apoptosis and high-temperature stress tolerance. Δcka2 mutants show reduced NO accumulation, decreased NOS-like activity, reduced apoptosis after H2O2, and hypersensitivity to high temperature.","method":"Gene deletion, NO measurement, NOS-like activity assay, survival assay with NO donor rescue","journal":"FEMS yeast research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic deletion with pharmacological rescue, multiple stress phenotypes","pmids":["26100262"],"is_preprint":false},{"year":2016,"finding":"CSNK2A1 (CK2α) physically binds to and phosphorylates SIRT6. Evidence includes co-immunoprecipitation, GST pull-down assay, in vitro kinase assay, and transfection of kinase-dead CSNK2A1. CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 promotes breast cancer cell proliferation and invasion; mutation of Ser338 inhibits MCF7 proliferation and decreases expression of MMP9, β-catenin, cyclin D1, and NF-κB.","method":"Co-immunoprecipitation, GST pull-down, in vitro kinase assay, site-directed mutagenesis, knockdown/overexpression with proliferation/invasion readouts","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (Co-IP, pulldown, in vitro kinase, mutagenesis) in single study","pmids":["27746184"],"is_preprint":false},{"year":2016,"finding":"De novo missense and canonical splice site mutations in CSNK2A1 cause a human neurodevelopmental syndrome (Okur-Chung syndrome) characterized by intellectual disability, developmental delay, hypotonia, speech problems, microcephaly, and dysmorphic features. This is the first report of germline CSNK2A1 mutations causing human disease.","method":"Whole exome sequencing of 4102 intellectual disability/developmental delay cases, identification of de novo variants","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 — large-scale WES with multiple independent de novo variants, defining new disease gene","pmids":["27048600"],"is_preprint":false},{"year":2019,"finding":"CSNK2A1 promotes gastric cancer invasion through the PI3K-Akt-mTOR signaling pathway and facilitates epithelial-mesenchymal transition (EMT). Overexpression of CSNK2A1 increases proliferation, invasion, and migration; silencing inhibits these processes. Western blot confirmed modulation of PI3K-Akt-mTOR pathway components.","method":"Stable overexpression and knockdown cell lines, invasion/migration assays, Western blot for pathway components","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 3 — KD/OE with pathway readout but no direct biochemical mechanism established","pmids":["31819646"],"is_preprint":false},{"year":2019,"finding":"The crystal structures of Cryptococcus neoformans CK2α ortholog (Cka1) in complex with AMPPNP-Mg2+ (2.40 Å) and CX-4945 inhibitor (2.09 Å) were solved. Structural comparison reveals dynamic architecture of the N-lobe across species. In vitro kinase assay demonstrated that CX-4945 inhibits human CK2α more efficiently than Cka1, explaining differences in binding affinity.","method":"X-ray crystallography, in vitro kinase inhibition assay","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional inhibition validation","pmids":["31591414"],"is_preprint":false},{"year":2020,"finding":"miR-1184 directly targets CSNK2A1 mRNA as validated by RNA immunoprecipitation and luciferase reporter assay. Overexpression of miR-1184 suppresses colon cancer cell proliferation and promotes apoptosis, effects reversed by CSNK2A1 overexpression, placing CSNK2A1 downstream of miR-1184 in this pathway.","method":"Luciferase reporter assay, RNA immunoprecipitation, overexpression/knockdown with functional rescue","journal":"Molecular and cellular probes","confidence":"Medium","confidence_rationale":"Tier 2 — direct target validation by two methods with functional rescue","pmids":["32619668"],"is_preprint":false},{"year":2020,"finding":"A novel chromosomal fusion gene CSNK2A1-PDGFRB was identified in myeloid neoplasm with eosinophilia. The fusion retains the entire kinase domain of PDGFRB and responds to imatinib at low concentration, resulting in sustained complete remission.","method":"RNA sequencing, RT-PCR, Sanger sequencing, clinical imatinib treatment response","journal":"Cancer research and treatment","confidence":"Medium","confidence_rationale":"Tier 2 — fusion gene characterized by multiple molecular methods with clinical functional consequence","pmids":["33421986"],"is_preprint":false},{"year":2021,"finding":"CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 activates the DNA damage repair pathway, conferring resistance to doxorubicin in osteosarcoma cells. Overexpression of CSNK2A1 induces resistance; knockdown potentiates cytotoxicity. In vivo, mutation of SIRT6 Ser338 attenuates CSNK2A1-mediated resistance. The CK2 inhibitor emodin potentiated doxorubicin cytotoxicity.","method":"Overexpression/knockdown, site-directed mutagenesis of phosphorylation site, in vivo xenograft model, pharmacological inhibition","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis of specific phosphorylation site with in vitro and in vivo validation","pmids":["34359939"],"is_preprint":false},{"year":2021,"finding":"CSNK2A1 binds to and phosphorylates HMGA2. LC-MS/MS identified high-potential HMGA2-CSNK2A1 interaction; immunoprecipitation confirmed binding; immunofluorescence showed co-localization in the nucleus. Cisplatin induces CSNK2A1-HMGA2 interaction and promotes HMGA2 phosphorylation; CX-4945 (CSNK2A1 inhibitor) blocks HMGA2 phosphorylation and sensitizes tumor cells to cisplatin.","method":"LC-MS/MS, co-immunoprecipitation, immunofluorescence, pharmacological inhibition with CX-4945","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 — MS-identified interaction confirmed by Co-IP and pharmacological validation","pmids":["34115920"],"is_preprint":false},{"year":2022,"finding":"The fission yeast CK2 catalytic subunit Cka1 phosphorylates the transcriptional coactivator PC4 at two serine residues, downregulating its RNA polymerase II coactivator function. The regulatory β-subunit (Ckb1) downregulates PC4 phosphorylation by Cka1. Mutation of both serine residues abolishes CK2 phosphorylation and the phosphorylation-insensitive mutant retains transcriptional coactivator activity even after Cka1 treatment.","method":"In vitro kinase assay, site-directed mutagenesis, in vitro transcription assay","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with mutagenesis and functional transcription assay","pmids":["36012759"],"is_preprint":false},{"year":2022,"finding":"Skeletal muscle-specific conditional knockout of CSNK2A1 in mice causes age-dependent reduced grip strength, impaired neuromuscular transmission, fragmented neuromuscular junctions (NMJs) with increased synaptic gene expression, increased central nuclei (muscle regeneration marker), impaired oxidative metabolism, and stimulated autophagy. Loss of CSNK2A1 also alters protein abundance of other CK2 subunits.","method":"Conditional knockout mouse (HSA-Cre), grip strength testing, electrophysiology, immunohistochemistry, enzyme activity assays, Western blot","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with multiple orthogonal readouts across muscle biology","pmids":["36552726"],"is_preprint":false},{"year":2022,"finding":"CircNDST1 binds CSNK2A1 protein directly (RNA pull-down and RIP validated) and promotes interaction between CSNK2A1 and AKT, leading to activation of the PI3K-Akt pathway and EMT in papillary thyroid cancer. Acting as a scaffold, circNDST1 enhances CSNK2A1-AKT physical association.","method":"RNA pull-down, RNA immunoprecipitation, Western blot for pathway activation, knockdown studies","journal":"Journal of endocrinological investigation","confidence":"Medium","confidence_rationale":"Tier 2 — direct RNA-protein binding validated by two methods with functional pathway consequence","pmids":["36306106"],"is_preprint":false},{"year":2023,"finding":"CSNK2A1-mediated phosphorylation of MAX shifts MAX from MAX-MAX homodimers to C-MYC-MAX and β-catenin-MAX heterodimers, increasing HMGB1 and IL-6 promoter activities. Overexpression of phosphorylated MAX promotes cell proliferation, migration, invasion, and cholangiocarcinogenesis; CX-4945 (CK2 inhibitor) reverses these effects.","method":"Co-immunoprecipitation, promoter activity assays, overexpression/knockdown, CX-4945 pharmacological inhibition, in vivo mouse model","journal":"Hepatology communications","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP with promoter activity and functional rescue by CK2 inhibitor","pmids":["37347224"],"is_preprint":false},{"year":2023,"finding":"DUSP2 competes with AKT1 to bind CSNK2A1, thereby inhibiting CSNK2A1-mediated phosphorylation of AKT1 and promoting apoptosis in pancreatic cancer. Aberrant AKT1 activation leads to TRIM21-mediated ubiquitination and proteasomal degradation of DUSP2, forming a positive feedback loop.","method":"Co-immunoprecipitation, competitive binding assay, phosphorylation analysis, in vitro and in vivo apoptosis assays","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP demonstrating competition, with in vitro and in vivo functional validation","pmids":["37390887"],"is_preprint":false},{"year":2023,"finding":"TMPO-AS1L lncRNA acts as a scaffold that strengthens the interaction between CSNK2A1 and DDX3X, activating Wnt/β-catenin signaling to promote prostate cancer bone metastasis.","method":"Co-immunoprecipitation, RNA pulldown, in vitro and in vivo functional assays","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — scaffold mechanism validated by Co-IP and RNA pulldown","pmids":["37542040"],"is_preprint":false},{"year":2024,"finding":"CSNK2A1 confers gemcitabine resistance in pancreatic ductal adenocarcinoma by activating autophagy. CSNK2A1 transcription is regulated by H3K27 acetylation. Silmitasertib (CSNK2A1 inhibitor) effectively inhibits autophagy and, in combination with gemcitabine, shows remarkable efficacy in PDAC patient-derived xenograft models.","method":"Bioinformatics, PDX model, siRNA knockdown, Silmitasertib pharmacological inhibition, autophagy assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — PDX model with pharmacological inhibition and mechanistic pathway analysis","pmids":["38290659"],"is_preprint":false},{"year":2024,"finding":"OGT promotes O-GlcNAc glycosylation of CSNK2A1, enhancing its protein stability. OGT-mediated glycosylation of CSNK2A1 reverses tumor suppression caused by CSNK2A1 knockdown, and CSNK2A1 promotes colorectal cancer progression via the PI3K/AKT pathway.","method":"Immunoprecipitation, Western blot, immunofluorescence for O-GlcNAc modification, knockdown rescue assay, tumor-bearing mouse model","journal":"Molecular biotechnology","confidence":"Medium","confidence_rationale":"Tier 2 — PTM validated by IP with functional rescue, in vivo model","pmids":["38289573"],"is_preprint":false},{"year":2024,"finding":"Cholesterol directly binds CSNK2A1 and augments its kinase activity, leading to phosphorylation of IGF2R at Ser2484. This cascade rewires lipid-driven mitochondrial oxidative phosphorylation and creates a positive feedback loop for cholesterol biosynthesis in hepatocellular carcinoma. Initial transcriptional activation of CSNK2A1 is driven by RAD21 upregulation.","method":"Proteomics, phosphoproteomics, cholesterol-binding assay, in vitro kinase assay, patient-derived organoids and xenografts","journal":"Journal of advanced research","confidence":"High","confidence_rationale":"Tier 1 — direct binding assay combined with in vitro kinase assay, phosphoproteomics, and in vivo validation","pmids":["39547439"],"is_preprint":false},{"year":2025,"finding":"SOX4 transcription factor upregulates CSNK2A1 expression by binding to its promoter (confirmed by ChIP and dual-luciferase reporter). Elevated CSNK2A1 phosphorylates TOP2A, promoting breast cancer cell proliferation, migration, invasion, and tumor growth in vivo. Silencing SOX4 reduces CSNK2A1-TOP2A phosphorylation and suppresses tumor growth.","method":"ChIP, dual-luciferase reporter assay, RT-qPCR, Western blot, CCK-8, colony formation, Transwell assay, mouse xenograft model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-confirmed transcriptional regulation with in vitro and in vivo functional validation","pmids":["39931818"],"is_preprint":false},{"year":2025,"finding":"S. pombe Cka1 (CK2α ortholog) interacts with components of the RSC chromatin remodeling complex, DNA packaging complexes, the Pcs1/Mde4 monopolin complex, and snoRNA-containing ribonucleoproteins and spliceosomal machinery. In vitro kinase assays confirmed that Cka1 directly phosphorylates Pcs1 and Mde4, monopolin subunits involved in mitotic division.","method":"RNase-free tandem affinity purification coupled with mass spectrometry, in vitro kinase assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — AP-MS interaction screen validated by direct in vitro kinase assay for specific substrates","pmids":["40700808"],"is_preprint":false},{"year":2025,"finding":"A frameshift mutation in CSNK2A1 (c.1020_1021delAG, p.Gly342Glnfs*57) significantly reduces protein expression through elevated ubiquitination-dependent proteasomal degradation, despite elevated mutant mRNA levels. In vitro kinase assay showed the variant did not impair intrinsic kinase activity, indicating the pathogenic mechanism is reduced protein abundance rather than catalytic dysfunction.","method":"In vitro kinase assay, quantitative mRNA/protein analysis, ubiquitination assay, bioinformatic structural prediction","journal":"Frontiers in genetics","confidence":"Medium","confidence_rationale":"Tier 1/2 — in vitro kinase assay with protein stability and ubiquitination functional analysis","pmids":["41216289"],"is_preprint":false},{"year":2025,"finding":"CSNK2A1 modulates dermal fibroblast senescence; ellagic acid upregulates CSNK2A1 expression, activates Nrf2, reduces ROS and inflammatory cytokines (IL-6, TNF-α, IL-1β) via NF-κB p65 inhibition. Silmitasertib (CSNK2A1 inhibitor) negates these anti-senescence effects, demonstrating CSNK2A1's role in oxidative stress and inflammation signaling.","method":"MTT assay, Western blot, fluorescence ROS staining, SA-β-gal staining, flow cytometry, TUNEL assay, pharmacological inhibition","journal":"Clinical, cosmetic and investigational dermatology","confidence":"Medium","confidence_rationale":"Tier 3 — pharmacological inhibition with multiple senescence readouts, mechanism inferred","pmids":["40860313"],"is_preprint":false},{"year":2025,"finding":"CK2 inhibitor CX-4945 decreases EWS-FLI1 oncoprotein abundance in Ewing sarcoma cells through increased ubiquitination and proteasomal degradation. Genetic inhibition of CK2 recapitulates this effect, demonstrating CSNK2A1-dependent stabilization of EWS-FLI1. CX-4945 shows anti-tumor activity in metastatic xenograft models and synergistic cytotoxicity with temozolomide and irinotecan.","method":"Genetic knockdown, pharmacological inhibition (CX-4945), ubiquitination assay, tumor organoids, patient-derived xenograft cells, in vivo xenograft model","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological concordance with mechanistic ubiquitination readout, preprint","pmids":["bio_10.1101_2025.09.24.677357"],"is_preprint":true}],"current_model":"CSNK2A1 encodes the catalytic α subunit of the constitutively active, ubiquitous serine/threonine kinase CK2, which forms an α2β2 tetrameric holoenzyme and phosphorylates over 100 substrates including SIRT6 (Ser338), PTEN (C-terminal cluster), α-synuclein (Ser129), p62/SQSTM1 (Ser403), HMGA2, MAX, TOP2A, AKT1, IGF2R (Ser2484), and Pcs1/Mde4; it localizes to both nucleus and cytoplasm, is essential for viability in yeast (via roles in cell polarity and the actin cytoskeleton), regulates autophagy, DNA damage repair, Wnt/β-catenin and PI3K-AKT-mTOR signaling, and protein stability (PTEN, EWS-FLI1); its stability is enhanced by OGT-mediated O-GlcNAcylation; cholesterol directly binds and activates it; and germline loss-of-function mutations cause Okur-Chung neurodevelopmental syndrome."},"narrative":{"teleology":[{"year":1988,"claim":"Identification of the yeast CKA1 gene as encoding the CK2 catalytic α subunit established genetic access to CK2 and revealed functional redundancy with CKA2.","evidence":"Gene isolation, sequencing, and gene disruption in S. cerevisiae","pmids":["3062376"],"confidence":"High","gaps":["Functional specialization between α and α′ not yet resolved","No mammalian ortholog characterization"]},{"year":1990,"claim":"Demonstrating that simultaneous loss of both catalytic subunits is lethal—rescued by Drosophila CK2α—established CK2 as an essential, evolutionarily conserved kinase.","evidence":"Double gene disruption and cross-species complementation in yeast","pmids":["2196445"],"confidence":"High","gaps":["Essential substrates not identified","Requirement for β subunit in vivo unclear"]},{"year":1992,"claim":"Purification of catalytically active free CK2α monomer from rescued yeast showed that the β subunit is dispensable for basal catalytic activity, defining CK2α as an autonomous kinase.","evidence":"Biochemical purification and in vitro kinase assays from genetically rescued strains","pmids":["1527008"],"confidence":"High","gaps":["Substrate specificity differences between free α and holoenzyme not resolved","In vivo relevance of monomeric activity uncertain"]},{"year":1998,"claim":"Temperature-sensitive CKA1 alleles revealed a specific role in cell polarity maintenance, with actin delocalization and multinucleate arrest, distinguishing CKA1 from CKA2 function.","evidence":"Conditional allele with fluorescence microscopy and cell cycle analysis in yeast","pmids":["9488724"],"confidence":"High","gaps":["Direct polarity substrates not identified","Mechanism linking CK2α to actin organization unknown"]},{"year":2000,"claim":"Identification of α-synuclein Ser129 as a constitutive CK2 phosphorylation site in vivo provided the first link between CK2 and neurodegeneration-associated substrates.","evidence":"Site-directed mutagenesis, in vitro kinase assay, 2D phosphopeptide mapping, and CK2 inhibitor treatment in cells","pmids":["10617630"],"confidence":"High","gaps":["Functional consequence of Ser129 phosphorylation on α-synuclein aggregation not determined in this study","Whether CK2 is the sole Ser129 kinase in vivo unclear"]},{"year":2001,"claim":"Demonstrating that CK2-mediated C-terminal phosphorylation of PTEN protects it from proteasomal degradation established CK2 as a regulator of tumor suppressor stability.","evidence":"In vitro kinase assay, phosphorylation-defective PTEN mutants, proteasome inhibitor and stability assays","pmids":["11035045"],"confidence":"High","gaps":["Identity of the E3 ligase targeting unphosphorylated PTEN not identified","In vivo relevance in tumor models not tested"]},{"year":2011,"claim":"CK2 phosphorylation of p62/SQSTM1 at Ser403 enhanced UBA domain affinity for polyubiquitin chains and autophagic clearance, directly linking CK2 to selective autophagy.","evidence":"In vitro kinase assay, mutagenesis, autophagy flux assays, and polyglutamine inclusion body assay","pmids":["22017874"],"confidence":"High","gaps":["Whether CK2 regulates autophagy through additional substrates beyond p62 not addressed","Tissue-specific relevance not tested"]},{"year":2016,"claim":"Discovery that de novo CSNK2A1 mutations cause Okur-Chung neurodevelopmental syndrome established the first Mendelian disease link and confirmed the gene's essential role in human brain development.","evidence":"Whole exome sequencing of 4102 intellectual disability cases with identification of multiple independent de novo variants","pmids":["27048600"],"confidence":"High","gaps":["Pathogenic mechanism (loss of kinase activity vs. dominant-negative vs. haploinsufficiency) not resolved","No functional assays on patient variants reported in this study"]},{"year":2016,"claim":"CK2α was shown to phosphorylate SIRT6 at Ser338, with downstream effects on β-catenin and NF-κB signaling in breast cancer, establishing SIRT6 as a functionally consequential CK2 substrate.","evidence":"Co-IP, GST pull-down, in vitro kinase assay, and site-directed mutagenesis with proliferation and invasion readouts","pmids":["27746184"],"confidence":"High","gaps":["Whether SIRT6 phosphorylation affects its deacetylase activity directly not measured","Generalizability beyond breast cancer not established"]},{"year":2021,"claim":"Extending the SIRT6 axis, CK2α-mediated Ser338 phosphorylation was shown to activate DNA damage repair and confer doxorubicin resistance in osteosarcoma, broadening CK2's role to chemoresistance.","evidence":"Site-directed mutagenesis, in vivo xenograft model, pharmacological inhibition with emodin","pmids":["34359939"],"confidence":"High","gaps":["Which specific DNA repair pathway is activated not delineated","Whether other CK2 substrates contribute to chemoresistance in parallel not tested"]},{"year":2022,"claim":"Muscle-specific Csnk2a1 knockout mice revealed age-dependent neuromuscular junction fragmentation, impaired oxidative metabolism, and stimulated autophagy, establishing CK2α as essential for mammalian skeletal muscle homeostasis.","evidence":"Conditional knockout (HSA-Cre), grip strength, electrophysiology, immunohistochemistry, and enzyme activity assays","pmids":["36552726"],"confidence":"High","gaps":["Direct phosphorylation substrates mediating NMJ maintenance not identified","Whether neuronal CK2α contributes to the phenotype not distinguished"]},{"year":2023,"claim":"CK2α phosphorylation of MAX was shown to shift MAX from homodimers to C-MYC–MAX and β-catenin–MAX heterodimers, activating HMGB1/IL-6 transcription, revealing a mechanism by which CK2 modulates MYC-dependent gene expression.","evidence":"Co-IP, promoter activity assays, CX-4945 inhibition, in vivo mouse model","pmids":["37347224"],"confidence":"Medium","gaps":["Specific phosphorylation site(s) on MAX not mapped in this study","Whether this mechanism operates in non-malignant contexts unknown"]},{"year":2024,"claim":"Cholesterol was identified as a direct CK2α-binding ligand that augments kinase activity and drives phosphorylation of IGF2R at Ser2484, creating a metabolic feedback loop coupling lipid sensing to mitochondrial oxidative phosphorylation.","evidence":"Cholesterol-binding assay, in vitro kinase assay, phosphoproteomics, patient-derived organoids and xenografts","pmids":["39547439"],"confidence":"High","gaps":["Structural basis of cholesterol–CK2α binding not resolved","Whether other lipids also modulate CK2 activity not tested"]},{"year":2024,"claim":"OGT-mediated O-GlcNAcylation of CK2α was shown to enhance its protein stability, identifying a post-translational mechanism that tunes CK2 abundance in colorectal cancer.","evidence":"Immunoprecipitation for O-GlcNAc modification, knockdown rescue, tumor-bearing mouse model","pmids":["38289573"],"confidence":"Medium","gaps":["Specific O-GlcNAcylation sites on CK2α not mapped","Whether O-GlcNAcylation affects kinase activity independently of stability not tested"]},{"year":2025,"claim":"A pathogenic frameshift variant in CSNK2A1 was shown to reduce protein abundance through elevated ubiquitination-dependent degradation rather than impairing catalytic activity, clarifying a loss-of-function mechanism in Okur-Chung syndrome.","evidence":"In vitro kinase assay, quantitative mRNA/protein analysis, ubiquitination assay","pmids":["41216289"],"confidence":"Medium","gaps":["Single variant studied; generalizability to other OCNDS variants unknown","No neuronal or brain-relevant model used"]},{"year":2025,"claim":"AP-MS of fission yeast Cka1 revealed interactions with RSC chromatin remodeling, monopolin, and spliceosomal complexes, with direct phosphorylation of monopolin subunits Pcs1 and Mde4 expanding CK2's role to chromosome segregation.","evidence":"RNase-free tandem affinity purification with mass spectrometry, in vitro kinase assay","pmids":["40700808"],"confidence":"Medium","gaps":["Functional consequence of monopolin phosphorylation on chromosome segregation fidelity not tested","Validation in mammalian systems absent"]},{"year":null,"claim":"Key unresolved questions include the structural basis for allosteric activation of CK2α by cholesterol and other ligands, the complete inventory of CK2α substrates that mediate neurodevelopmental pathology in Okur-Chung syndrome, and whether monomeric versus holoenzyme CK2α pools have distinct substrate selectivity in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of cholesterol–CK2α complex","Neuronal substrates relevant to OCNDS not identified","In vivo partitioning between monomeric and holoenzyme CK2α activity not measured"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,4,7,8,9,12,15,20,24,28,29,30]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[7,8,9,12,20,24,28,29,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,19]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,14,22,23,24,25,28]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[9,21,26]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,6,30]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,10,27,31]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,14,17,23,26,29]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,24]}],"complexes":["CK2 holoenzyme (α2β2 tetramer)"],"partners":["CSNK2B","SIRT6","PTEN","SQSTM1","AKT1","HMGA2","MAX","DDX3X"],"other_free_text":[]},"mechanistic_narrative":"CSNK2A1 encodes the catalytic α subunit of casein kinase II (CK2), a constitutively active, ubiquitous serine/threonine kinase that assembles into an α2β2 tetrameric holoenzyme and phosphorylates more than 100 substrates to regulate cell division, signal transduction, protein stability, autophagy, and DNA damage repair [PMID:7896000, PMID:22017874, PMID:34359939]. CK2α is essential for viability—demonstrated by lethality of dual catalytic-subunit deletion in yeast—and functions in cell polarity and actin cytoskeleton organization; in mouse skeletal muscle, conditional loss causes neuromuscular junction fragmentation, impaired oxidative metabolism, and stimulated autophagy [PMID:2196445, PMID:9488724, PMID:36552726]. Key substrates include PTEN (C-terminal phosphorylation stabilizing the protein against proteasomal degradation), α-synuclein (Ser129), p62/SQSTM1 (Ser403, enhancing autophagic clearance), SIRT6 (Ser338, activating DNA damage repair), AKT1, MAX, and IGF2R (Ser2484), with CK2α activity itself modulated by cholesterol binding and OGT-mediated O-GlcNAcylation [PMID:11035045, PMID:10617630, PMID:22017874, PMID:27746184, PMID:39547439, PMID:38289573]. Germline loss-of-function mutations in CSNK2A1 cause Okur-Chung neurodevelopmental syndrome [PMID:27048600]."},"prefetch_data":{"uniprot":{"accession":"P68400","full_name":"Casein kinase II subunit alpha","aliases":[],"length_aa":391,"mass_kda":45.1,"function":"Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine (PubMed:11239457, PubMed:11704824, PubMed:16193064, PubMed:18411307, PubMed:18583988, PubMed:18678890, PubMed:19188443, PubMed:20545769, PubMed:20625391, PubMed:22017874, PubMed:22406621, PubMed:24962073, PubMed:30898438, PubMed:31439799). Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection (PubMed:12631575, PubMed:19387551, PubMed:19387552). May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response (PubMed:12631575, PubMed:19387551, PubMed:19387552). During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage (PubMed:11704824, PubMed:19188443). Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation (PubMed:11239457). Phosphorylates a number of DNA repair proteins in response to DNA damage, such as MDC1, MRE11, RAD9A, RAD51 and HTATSF1, promoting their recruitment to DNA damage sites (PubMed:18411307, PubMed:18583988, PubMed:18678890, PubMed:20545769, PubMed:21482717, PubMed:22325354, PubMed:26811421, PubMed:28512243, PubMed:30898438, PubMed:35597237). Can also negatively regulate apoptosis (PubMed:16193064, PubMed:22184066). Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3 (PubMed:16193064). Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8 (PubMed:16193064). Phosphorylates YY1, protecting YY1 from cleavage by CASP7 during apoptosis (PubMed:22184066). Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552, PubMed:23123191). Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, ATF4, SRF, MAX, JUN, FOS, MYC and MYB (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552, PubMed:23123191). Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function (PubMed:19387550). Mediates sequential phosphorylation of FNIP1, promoting its gradual interaction with Hsp90, leading to activate both kinase and non-kinase client proteins of Hsp90 (PubMed:30699359). Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1 (PubMed:19387549). Acts as an ectokinase that phosphorylates several extracellular proteins (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552). During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV (PubMed:12631575, PubMed:19387550, PubMed:19387551, PubMed:19387552). Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation (PubMed:20625391, PubMed:22406621). Plays an important role in the circadian clock function by phosphorylating BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry (By similarity). Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue (PubMed:24962073). Phosphorylates FMR1, promoting FMR1-dependent formation of a membraneless compartment (PubMed:30765518, PubMed:31439799). May phosphorylate histone H2A on 'Ser-1' (PubMed:38334665)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P68400/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSNK2A1","classification":"Not Classified","n_dependent_lines":85,"n_total_lines":1208,"dependency_fraction":0.07036423841059603},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000101266","cell_line_id":"CID000855","localizations":[{"compartment":"big_aggregates","grade":3},{"compartment":"cytoplasmic","grade":3},{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"NCL","stoichiometry":10.0},{"gene":"CSNK2B","stoichiometry":10.0},{"gene":"CEP170","stoichiometry":4.0},{"gene":"HDAC2","stoichiometry":4.0},{"gene":"POLR2F","stoichiometry":4.0},{"gene":"RBBP4","stoichiometry":4.0},{"gene":"RPL27","stoichiometry":4.0},{"gene":"RPS16","stoichiometry":4.0},{"gene":"KIF1B","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000855","total_profiled":1310},"omim":[{"mim_id":"619818","title":"ELONGATION FACTOR 1; ELOF1","url":"https://www.omim.org/entry/619818"},{"mim_id":"618732","title":"POIRIER-BIENVENU NEURODEVELOPMENTAL SYNDROME; POBINDS","url":"https://www.omim.org/entry/618732"},{"mim_id":"617062","title":"OKUR-CHUNG NEURODEVELOPMENTAL SYNDROME; OCNDS","url":"https://www.omim.org/entry/617062"},{"mim_id":"614854","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 59; LRRC59","url":"https://www.omim.org/entry/614854"},{"mim_id":"613110","title":"BLCAP APOPTOSIS-INDUCING FACTOR; BLCAP","url":"https://www.omim.org/entry/613110"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CSNK2A1"},"hgnc":{"alias_symbol":["Cka1","Cka2"],"prev_symbol":[]},"alphafold":{"accession":"P68400","domains":[{"cath_id":"3.30.200.20","chopping":"24-113","consensus_level":"medium","plddt":96.2103,"start":24,"end":113},{"cath_id":"1.10.510.10","chopping":"120-334","consensus_level":"high","plddt":97.6454,"start":120,"end":334}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P68400","model_url":"https://alphafold.ebi.ac.uk/files/AF-P68400-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P68400-F1-predicted_aligned_error_v6.png","plddt_mean":88.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSNK2A1","jax_strain_url":"https://www.jax.org/strain/search?query=CSNK2A1"},"sequence":{"accession":"P68400","fasta_url":"https://rest.uniprot.org/uniprotkb/P68400.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P68400/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P68400"}},"corpus_meta":[{"pmid":"2196445","id":"PMC_2196445","title":"Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2196445","citation_count":331,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3062376","id":"PMC_3062376","title":"Isolation, sequencing, and disruption of the CKA1 gene encoding the alpha subunit of yeast casein kinase II.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3062376","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27746184","id":"PMC_27746184","title":"CK2α/CSNK2A1 Phosphorylates SIRT6 and Is Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of Diagnosed Patients.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27746184","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27048600","id":"PMC_27048600","title":"De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features.","date":"2016","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27048600","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30655572","id":"PMC_30655572","title":"Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures.","date":"2019","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30655572","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9488724","id":"PMC_9488724","title":"Temperature-sensitive mutations of the CKA1 gene reveal a role for casein kinase II in maintenance of cell polarity in Saccharomyces cerevisiae.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9488724","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1527008","id":"PMC_1527008","title":"Purification and characterization of casein kinase II (CKII) from delta cka1 delta cka2 Saccharomyces cerevisiae rescued by Drosophila CKII subunits. The free catalytic subunit of casein kinase II is not toxic in vivo.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1527008","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8188256","id":"PMC_8188256","title":"The human gene (CSNK2A1) coding for the casein kinase II subunit alpha is located on chromosome 20 and contains tandemly arranged Alu repeats.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8188256","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29383814","id":"PMC_29383814","title":"Extending the phenotype associated with the CSNK2A1-related Okur-Chung syndrome-A clinical study of 11 individuals.","date":"2018","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/29383814","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9503018","id":"PMC_9503018","title":"Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit alpha (CSNK2A1).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9503018","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31819646","id":"PMC_31819646","title":"CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31819646","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34038195","id":"PMC_34038195","title":"Identification of novel CSNK2A1 variants and the genotype-phenotype relationship in patients with Okur-Chung neurodevelopmental syndrome: a case report and systematic literature review.","date":"2021","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/34038195","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37390887","id":"PMC_37390887","title":"DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37390887","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36271116","id":"PMC_36271116","title":"In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36271116","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32619668","id":"PMC_32619668","title":"miR-1184 regulates the proliferation and apoptosis of colon cancer cells via targeting CSNK2A1.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/32619668","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34359939","id":"PMC_34359939","title":"CK2α/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34359939","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38290659","id":"PMC_38290659","title":"CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38290659","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37542040","id":"PMC_37542040","title":"The long transcript of lncRNA TMPO-AS1 promotes bone metastases of prostate cancer by regulating the CSNK2A1/DDX3X complex in Wnt/β-catenin signaling.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37542040","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36213692","id":"PMC_36213692","title":"Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer.","date":"2022","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/36213692","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36310603","id":"PMC_36310603","title":"Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36310603","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36306106","id":"PMC_36306106","title":"CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition.","date":"2022","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36306106","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37391010","id":"PMC_37391010","title":"P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37391010","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31060130","id":"PMC_31060130","title":"[A case of Okur-Chung syndrome caused by CSNK2A1 gene variation and review of literature].","date":"2019","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/31060130","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26100262","id":"PMC_26100262","title":"CKA2 functions in H2O2-induced apoptosis and high-temperature stress tolerance by regulating NO accumulation in yeast.","date":"2015","source":"FEMS yeast research","url":"https://pubmed.ncbi.nlm.nih.gov/26100262","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32472542","id":"PMC_32472542","title":"[Identification of a novel de novo variant of CSNK2A1 gene in a boy with Okur-Chung neurodevelopmental syndrome].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32472542","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21453497","id":"PMC_21453497","title":"The loop-less tmCdc34 E2 mutant defective in polyubiquitination in vitro and in vivo supports yeast growth in a manner dependent on Ubp14 and Cka2.","date":"2011","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/21453497","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34115920","id":"PMC_34115920","title":"CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/34115920","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37347224","id":"PMC_37347224","title":"CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression.","date":"2023","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/37347224","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38289573","id":"PMC_38289573","title":"O-GlcNAcylation of CSNK2A1 by OGT is Involved in the Progression of Colorectal Cancer.","date":"2024","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38289573","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33421986","id":"PMC_33421986","title":"Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.","date":"2020","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33421986","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37491870","id":"PMC_37491870","title":"Inherited CSNK2A1 variants in families with Okur-Chung neurodevelopmental syndrome.","date":"2023","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37491870","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34306196","id":"PMC_34306196","title":"Long non-coding RNA B3GALT5-AS1 contributes to the progression of gastric cancer via interacting with CSNK2A1.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34306196","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39547439","id":"PMC_39547439","title":"Oncogenic cholesterol rewires lipid metabolism in hepatocellular carcinoma via the CSNK2A1-IGF2R Ser2484 axis.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/39547439","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38357263","id":"PMC_38357263","title":"A Case of Okur-Chung Neurodevelopmental Syndrome with a Novel, de novo Variant on the CSNK2A1 Gene in a Turkish Patient.","date":"2023","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/38357263","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31591414","id":"PMC_31591414","title":"Structural analysis of fungal pathogenicity-related casein kinase α subunit, Cka1, in the human fungal pathogen Cryptococcus neoformans.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31591414","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39497417","id":"PMC_39497417","title":"Expanding the phenotypic spectrum of CSNK2A1-associated Okur-Chung neurodevelopmental syndrome.","date":"2024","source":"HGG advances","url":"https://pubmed.ncbi.nlm.nih.gov/39497417","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39253198","id":"PMC_39253198","title":"Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39253198","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7909530","id":"PMC_7909530","title":"PstI identifies biallelic DNA polymorphism of the human casein kinase 2 alpha gene (CSNK2A1).","date":"1994","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7909530","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39931818","id":"PMC_39931818","title":"Novel role of the SOX4/CSNK2A1 axis in regulating TOP2A phosphorylation in breast cancer progression.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39931818","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36012759","id":"PMC_36012759","title":"The Catalytic Subunit of Schizosaccharomyces pombe CK2 (Cka1) Negatively Regulates RNA Polymerase II Transcription through Phosphorylation of Positive Cofactor 4 (PC4).","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012759","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40742416","id":"PMC_40742416","title":"Clinical and molecular results in 15 Turkish patients with Wiedemann-Steiner syndrome: identification of eight novel KMT2A variants and a case of dual molecular diagnosis in the CSNK2A1.","date":"2025","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/40742416","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40860313","id":"PMC_40860313","title":"Ellagic Acid Mediates the Delay of Dermal Fibroblast Senescence via CSNK2A1.","date":"2025","source":"Clinical, cosmetic and investigational dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/40860313","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38711237","id":"PMC_38711237","title":"Patient with a heterozygous pathogenic variant in CSNK2A1 gene: A new case to update the Okur-Chung neurodevelopmental syndrome.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/38711237","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36552726","id":"PMC_36552726","title":"In Skeletal Muscle Fibers, Protein Kinase Subunit CSNK2A1/CK2α Is Required for Proper Muscle Homeostasis and Structure and Function of Neuromuscular Junctions.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36552726","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40700808","id":"PMC_40700808","title":"Exploring the Cka1 kinase interactome: unveiling novel potential regulatory roles of CKII kinase in S. pombe.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/40700808","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39403680","id":"PMC_39403680","title":"A guide to selecting high-performing antibodies for CSNK2A1 (UniProt ID: P68400) for use in western blot, immunoprecipitation and immunofluorescence.","date":"2024","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/39403680","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41395761","id":"PMC_41395761","title":"A Case of CSNK2A1 Gene Variant Causing Okur-Chung Syndrome and Analysis of the Clinical Phenotypic Spectrum.","date":"2025","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41395761","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41216289","id":"PMC_41216289","title":"Identification and functional analysis of a novel CSNK2A1 frameshift variant in stillbirth.","date":"2025","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41216289","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.27.691040","title":"An inositol pyrophosphate interaction screen provides insight into the regulation of plant casein kinase II","date":"2025-11-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.27.691040","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.09.24.677357","title":"CK2 inhibitor CX-4945 targets EWS-FLI1 protein abundance and shows anti-tumor activity in metastatic mouse models of Ewing Sarcoma","date":"2025-09-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.24.677357","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.25.656027","title":"Identifying Molecular Determinants and Therapeutic Targets in Luminal B Breast Cancer: A Systems Biology Approach","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.25.656027","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.04.01.646642","title":"Altered Protein Phosphorylation in a Novel Midbrain Organoid Model for Bipolar Disorder","date":"2025-04-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.01.646642","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.27.24314463","title":"Identification of genetic variants and their causal association underlying autism spectrum disorder","date":"2024-09-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.27.24314463","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"17580304","id":"PMC_17580304","title":"p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17580304","citation_count":3823,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21906983","id":"PMC_21906983","title":"Systematic and quantitative assessment of the ubiquitin-modified proteome.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21906983","citation_count":1334,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11390642","id":"PMC_11390642","title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11390642","citation_count":909,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21890473","id":"PMC_21890473","title":"A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles.","date":"2011","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/21890473","citation_count":749,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22325352","id":"PMC_22325352","title":"PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22325352","citation_count":698,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7896000","id":"PMC_7896000","title":"Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation.","date":"1995","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/7896000","citation_count":577,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22017874","id":"PMC_22017874","title":"Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22017874","citation_count":571,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33060197","id":"PMC_33060197","title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33060197","citation_count":564,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11035045","id":"PMC_11035045","title":"The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11035045","citation_count":555,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10617630","id":"PMC_10617630","title":"Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10617630","citation_count":444,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7790358","id":"PMC_7790358","title":"Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function.","date":"1995","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7790358","citation_count":427,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507397","id":"PMC_29507397","title":"Polyubiquitin chain-induced p62 phase separation drives autophagic cargo segregation.","date":"2018","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29507397","citation_count":424,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23463506","id":"PMC_23463506","title":"The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23463506","citation_count":413,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29313,"output_tokens":5002,"usd":0.081485},"stage2":{"model":"claude-opus-4-6","input_tokens":8533,"output_tokens":4301,"usd":0.225285},"total_usd":0.667499,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":41241,"output_tokens":8548,"usd":0.125971},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12206,"output_tokens":3819,"usd":0.234758}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"CSNK2A1 (CKA1) encodes the 42 kDa alpha catalytic subunit of yeast casein kinase II; null mutation of CKA1 alone is phenotypically wild type due to redundancy with the alpha' (CKA2) subunit, establishing that CKA1 and CKA2 encode two distinct catalytic subunits of the same holoenzyme.\",\n      \"method\": \"Gene disruption (null allele by gene replacement), biochemical fractionation, amino acid sequencing\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — gene disruption with defined phenotypic readout; foundational paper with >100 citations\",\n      \"pmids\": [\"3062376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Simultaneous disruption of both yeast CKA1 and CKA2 genes (encoding the two catalytic subunits of CKII) is lethal; cells depleted of CKII activity enlarge and arrest with a pseudomycelial morphology and flocculation. Viability was rescued by Drosophila CK2 alpha subunit alone, demonstrating functional conservation of the catalytic subunit across evolution.\",\n      \"method\": \"Double gene disruption (gene replacement), phenotypic analysis, cross-species complementation with Drosophila CKII subunits\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic epistasis with multiple orthogonal readouts; >300 citations\",\n      \"pmids\": [\"2196445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Yeast CKII holoenzyme purified as an alpha2-beta2 tetramer; the free catalytic alpha subunit monomer is catalytically active in vitro, and overexpression of free catalytic subunit is non-toxic in vivo, establishing that the regulatory beta subunit is dispensable for catalytic activity but affects holoenzyme assembly.\",\n      \"method\": \"Biochemical purification from GAL1/10-rescued yeast strains, in vitro kinase assay, quantitation of overexpression phenotype\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution and purification with in vitro kinase assay; >40 citations\",\n      \"pmids\": [\"1527008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Temperature-sensitive CKA1 mutations in yeast reveal a specific role for the CKA1-encoded catalytic subunit in maintenance of cell polarity: cka1(ts) cka2 cells arrest with a non-polarized actin cytoskeleton, delocalized chitin deposition, and multinucleate cell bodies, demonstrating functional specialization between the two catalytic subunits.\",\n      \"method\": \"Temperature-sensitive alleles, conditional growth arrest, actin cytoskeleton staining, chitin localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional alleles with multiple cellular phenotype readouts; >60 citations\",\n      \"pmids\": [\"9488724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CSNK2A1 binds to and phosphorylates SIRT6 (at Ser338); CSNK2A1-mediated SIRT6 phosphorylation promotes breast cancer cell proliferation and invasion, and increases expression of MMP9, β-catenin, cyclin D1, and NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, in vitro kinase assay, site-directed mutagenesis of SIRT6 Ser338, siRNA knockdown, immunofluorescence co-localization\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Co-IP, GST pulldown, in vitro kinase assay, mutagenesis) in a single study\",\n      \"pmids\": [\"27746184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 activates the DNA damage repair pathway and confers resistance to doxorubicin in osteosarcoma cells; mutation of SIRT6 Ser338 attenuates this resistance in vivo.\",\n      \"method\": \"CSNK2A1 overexpression/knockdown, Ser338 site mutagenesis, doxorubicin cytotoxicity assays in vitro and in vivo (xenograft), Western blot of DNA damage repair markers\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic follow-up with in vivo validation but primarily from a single lab\",\n      \"pmids\": [\"34359939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2A1 binds to and phosphorylates HMGA2; cisplatin treatment promotes CSNK2A1-HMGA2 interaction and HMGA2 phosphorylation, contributing to cisplatin resistance in cervical cancer; inhibition of CSNK2A1 with CX-4945 suppresses HMGA2 phosphorylation and sensitizes cells to cisplatin.\",\n      \"method\": \"LC-MS/MS protein interaction screen, co-immunoprecipitation, immunofluorescence co-localization, CSNK2A1 inhibitor (CX-4945) treatment\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (mass spec, Co-IP, IF) in single study; moderate evidence\",\n      \"pmids\": [\"34115920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CSNK2A1 phosphorylates MAX (MYC-associated factor X), which shifts MAX-MAX homodimers to C-MYC-MAX and β-catenin-MAX heterodimers, increasing HMGB1 and IL-6 promoter activities and driving cholangiocarcinoma progression; CK2 inhibitor CX-4945 reverses these effects.\",\n      \"method\": \"Overexpression/silencing of MAX and CSNK2A1, reporter gene (luciferase) assay for HMGB1/IL-6 promoters, protein half-life assay, in vitro and in vivo cellular assays, CX-4945 treatment\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter assays and functional rescue; single lab but multiple readouts\",\n      \"pmids\": [\"37347224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DUSP2 competes with AKT1 to bind CSNK2A1, thereby inhibiting CSNK2A1-mediated phosphorylation of AKT1 and promoting apoptosis in pancreatic cancer; AKT1 activation in turn drives TRIM21-mediated ubiquitination and proteasomal degradation of DUSP2, forming a feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, competition binding assays, phosphorylation assays, siRNA knockdown, in vivo xenograft models\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and in vivo validation; single lab\",\n      \"pmids\": [\"37390887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"lncRNA TMPO-AS1L acts as a scaffold to strengthen the CSNK2A1-DDX3X protein complex, activating Wnt/β-catenin signaling to promote prostate cancer bone metastasis.\",\n      \"method\": \"RNA immunoprecipitation, protein Co-IP, in vitro and in vivo bone metastasis assays, Wnt/β-catenin reporter assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — RNA-protein interaction and Co-IP with functional in vivo readout; single lab\",\n      \"pmids\": [\"37542040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"circNDST1 binds to CSNK2A1 via RNA-protein interaction and promotes the interaction between CSNK2A1 and AKT, leading to PI3K-Akt pathway activation and EMT in papillary thyroid cancer.\",\n      \"method\": \"RNA pull-down, RNA immunoprecipitation, Co-IP, Western blot, in vitro invasion/migration assays\",\n      \"journal\": \"Journal of endocrinological investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — RNA pull-down and Co-IP with functional readouts; single lab\",\n      \"pmids\": [\"36306106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cholesterol directly binds to CSNK2A1 and augments its kinase activity, leading to phosphorylation of IGF2R at Ser2484; this cascade rewires mitochondrial oxidative phosphorylation and generates reactive oxygen species, creating a positive feedback loop for cholesterol biosynthesis in hepatocellular carcinoma.\",\n      \"method\": \"Phosphoproteomics, in vitro kinase assay, cholesterol binding assay, patient-derived organoids and xenografts, malondialdehyde assay for ROS\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — phosphoproteomics and in vitro kinase assay; single study with multiple validation models\",\n      \"pmids\": [\"39547439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OGT (O-GlcNAc transferase) promotes O-GlcNAcylation of CSNK2A1, enhancing CSNK2A1 protein stability and promoting colorectal cancer progression via the PI3K/AKT pathway.\",\n      \"method\": \"Immunoprecipitation, Western blot for O-GlcNAc modification, immunofluorescence, knockdown/overexpression, tumor-bearing mouse model\",\n      \"journal\": \"Molecular biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and IF demonstrate O-GlcNAcylation; functional validation in vivo; single lab\",\n      \"pmids\": [\"38289573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Muscle-specific conditional knockout of CSNK2A1 in mice causes age-dependent muscle weakness with impaired neuromuscular transmission, increased regenerating (centrally nucleated) fibers, impaired oxidative metabolism, stimulated autophagy, NMJ fragmentation, and altered expression of other CSNK2 subunits; this establishes CSNK2A1 as required for skeletal muscle homeostasis and neuromuscular junction integrity.\",\n      \"method\": \"Conditional knockout mouse (HSA-Cre), grip strength measurement, electromyography, histology (central nuclei, cytochrome oxidase staining), Western blot, synaptic gene expression analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with multiple defined phenotypic readouts; single lab\",\n      \"pmids\": [\"36552726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A CSNK2A1 frameshift mutation (c.1020_1021delAG) significantly reduces protein expression due to elevated ubiquitination and proteasomal degradation of the mutant protein, despite elevated mRNA levels; in vitro kinase assay showed this variant did not impair kinase activity, indicating the pathogenic mechanism is loss of protein abundance.\",\n      \"method\": \"In vitro kinase assay, Western blot for ubiquitination, quantitative mRNA/protein analysis, overexpression of wild-type vs. mutant constructs\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay plus ubiquitination assay; single study\",\n      \"pmids\": [\"41216289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SOX4 transcription factor directly drives CSNK2A1 transcription; increased CSNK2A1 in turn phosphorylates TOP2A, promoting breast cancer cell proliferation, migration, invasion, and tumor growth in vivo.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay for CSNK2A1 promoter, Western blot for TOP2A phosphorylation, SOX4 silencing in vitro and in mouse models\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and promoter reporter establish transcriptional regulation; phosphorylation assay and in vivo validation\",\n      \"pmids\": [\"39931818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"P300-mediated H3K27 acetylation at the CSNK2A1 promoter drives increased CSNK2A1 expression in colorectal cancer, which in turn activates the PI3K-AKT-mTOR axis to promote EMT and cell invasion.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), UCSC bioinformatics, CSNK2A1 overexpression/knockdown, PI3K inhibitor rescue, Western blot for EMT markers and AKT/mTOR phosphorylation\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP establishes epigenetic regulation; pathway rescue with PI3K inhibitor; single lab\",\n      \"pmids\": [\"37391010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Yeast Cka2 kinase phosphorylates C-terminal serines of the E2 ubiquitin-conjugating enzyme Cdc34, which prevents synthesis of free polyubiquitin chains and promotes attachment of ubiquitin chains to substrate, thereby regulating polyubiquitination specificity.\",\n      \"method\": \"In vitro ubiquitination assay, in vivo polyubiquitin chain analysis, yeast genetics (ubp14 and cka2 mutants), protein biochemistry\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro ubiquitination assays plus genetic epistasis; single study\",\n      \"pmids\": [\"21453497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CSNK2A1 activates autophagy in pancreatic ductal adenocarcinoma; its transcriptional regulation is mediated by H3K27 acetylation at the CSNK2A1 promoter; enhanced autophagy drives gemcitabine resistance; CSNK2A1 inhibition by silmitasertib blocks autophagy and restores gemcitabine sensitivity.\",\n      \"method\": \"siRNA knockdown, patient-derived xenograft (PDX) model, autophagy flux assays, ChIP for H3K27ac, silmitasertib treatment in vitro and in vivo\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — PDX model plus ChIP and functional rescue; single lab\",\n      \"pmids\": [\"38290659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In fission yeast (S. pombe), CK2 catalytic subunit Cka1 phosphorylates PC4 (positive cofactor 4) at two serine residues, which downregulates PC4's RNA polymerase II coactivator function; the regulatory subunit Ckb1 inhibits this phosphorylation, establishing a regulatory mechanism for RNAPII transcription by CK2.\",\n      \"method\": \"In vitro kinase assay, in vitro transcription assay, site-directed mutagenesis of PC4 serine residues, addition of recombinant proteins to cell extract transcription system\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and transcription assay; single study\",\n      \"pmids\": [\"36012759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CSNK2A1 is identified as a direct target of miR-1184 in colon cancer; miR-1184 directly binds the CSNK2A1 3'UTR, reducing CSNK2A1 expression and thereby inhibiting cell proliferation and promoting apoptosis; CSNK2A1 overexpression reverses these effects.\",\n      \"method\": \"RNA immunoprecipitation, luciferase reporter gene assay for 3'UTR binding, CCK8, flow cytometry, colony formation, Western blot\",\n      \"journal\": \"Molecular and cellular probes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — RIP and luciferase reporter confirm direct miRNA targeting; functional rescue; single lab\",\n      \"pmids\": [\"32619668\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSNK2A1 encodes the alpha catalytic subunit of protein kinase CK2, a constitutively active serine/threonine kinase that functions as a free monomer or within an alpha2-beta2 holoenzyme; it phosphorylates diverse substrates including SIRT6 (Ser338), AKT1, HMGA2, MAX, TOP2A, PC4, and IGF2R (Ser2484), is activated by cholesterol binding and regulated by O-GlcNAcylation and by epigenetic (H3K27ac/P300/SOX4) transcriptional control, is required for cell polarity, neuromuscular junction integrity, and cell viability in model organisms, and drives cancer progression and chemoresistance through PI3K-AKT-mTOR, Wnt/β-catenin, DNA damage repair, and autophagy pathways.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper, then extract discoveries from KEPT papers only.\n\n**Classification notes:**\n- Papers [1],[2],[6],[7],[24],[26],[40],[45] — yeast/fission yeast CKA1/CKA2 orthologs → KEEP (orthologous function)\n- Papers [3],[4],[5],[9],[11],[12],[13],[15],[16],[17],[18],[19],[20],[21],[22],[23],[25],[27],[28],[29],[30],[31],[32],[33],[34],[36],[37],[38],[39],[42],[43],[44],[47],[48],[50],[52] — canonical human CSNK2A1 → KEEP\n- Paper [8],[10] — genomic organization of CSNK2A1 → KEEP (structural/regulatory info)\n- Paper [14] — in silico drug study → limited mechanistic content; KEEP for computational binding\n- Paper [35] — Cryptococcus CK2α structure (fungal pathogen, not ortholog of mammalian gene in same sense, but CK2α is conserved) → KEEP as structural ortholog\n- Paper [49] — Arabidopsis AtCKA1 (plant CK2α) → EXCLUDE (symbol collision, plant gene, fundamentally different cellular context)\n- Paper [41] — dual diagnosis case report, no mechanistic data → limited\n- Papers from gene2pubmed curated list: [1] p62/LC3 — about p62/SQSTM1 not CSNK2A1 directly; [20] CK2 phosphorylates p62 at S403 → KEEP; [22] CK2 phosphorylates PTEN → KEEP; [23] CK2 phosphorylates alpha-synuclein → KEEP; [19] CK2 review → KEEP; others are large-scale proteomics/interactome studies with CSNK2A1 as one of many proteins → limited specific mechanistic content\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"The CKA1 gene of S. cerevisiae encodes the 42 kDa alpha catalytic subunit of casein kinase II, which is 67% identical to the Drosophila CK2α. Null mutations in CKA1 alone are phenotypically wild type, indicating functional redundancy with the alpha' subunit encoded by CKA2.\",\n      \"method\": \"Gene isolation, sequencing, gene replacement/disruption\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct gene disruption with defined phenotypic readout, sequence-level characterization\",\n      \"pmids\": [\"3062376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"CK2 catalytic activity (encoded by CKA1 and CKA2) is essential for viability in S. cerevisiae; simultaneous disruption of both catalytic subunit genes is lethal. Cells depleted of CK2 activity arrest with increased cell size and a pseudomycelial morphology. Yeast lacking both endogenous catalytic subunits are rescued by expression of Drosophila CK2α alone (free monomeric catalytic subunit) or α+β, demonstrating evolutionary conservation of function.\",\n      \"method\": \"Double gene disruption, complementation with Drosophila subunits, genetic rescue assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution/rescue genetics with defined lethal phenotype, replicated across constructs\",\n      \"pmids\": [\"2196445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The free monomeric CK2α catalytic subunit is not toxic in vivo and is sufficient to rescue lethality of cka1/cka2 double disruption. CK2 purified from rescued strains shows that free alpha monomer is catalytically active; overexpression of total CK2 activity 6–18 fold has no overt phenotypic consequence.\",\n      \"method\": \"Purification and biochemical characterization of CK2 from genetically rescued yeast strains, in vitro kinase assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, purification, and in vitro activity assays\",\n      \"pmids\": [\"1527008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human CSNK2A1 gene is located on chromosome 20p13. The gene contains tandemly arranged Alu repeats within introns and consists of at least 8 exons (bases 102–824 of coding region characterized). Exon/intron boundaries conform to the gt/ag rule.\",\n      \"method\": \"Genomic cloning, sequencing, FISH chromosomal localization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping and structural characterization\",\n      \"pmids\": [\"8188256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CK2 is a ubiquitous eukaryotic serine/threonine kinase that phosphorylates more than 100 substrates involved in cell division and signal transduction. The α subunit is the catalytic subunit and the β subunit is regulatory; they form an α2β2 tetrameric holoenzyme. CK2 activity is constitutive and is present in both nucleus and cytoplasm.\",\n      \"method\": \"Biochemical characterization, review of in vitro kinase assays across multiple studies\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — extensive biochemical evidence compiled across many studies, widely replicated\",\n      \"pmids\": [\"7896000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The complete human CSNK2A1 gene spans 70 kb and consists of 13 exons. The promoter lacks a TATA box, contains a CpG island and GC boxes, characteristic of a housekeeping gene. Promoter activity was confirmed by reporter gene assay within the region from position −256 to +144. Two transcription start sites were identified by primer extension.\",\n      \"method\": \"Genomic cloning, sequencing, reporter gene assay, primer extension\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental characterization of promoter activity\",\n      \"pmids\": [\"9503018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Temperature-sensitive mutations in yeast CKA1 reveal a specific role for CK2α in maintenance of cell polarity. cka1(ts) strains arrest with nonpolarized actin cytoskeleton, delocalized chitin deposition, and multinucleate cell bodies, demonstrating functional specialization of CKA1 versus CKA2 catalytic subunits.\",\n      \"method\": \"Temperature-sensitive allele generation, fluorescence microscopy, cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional allele with multiple orthogonal phenotypic readouts (actin, chitin, nuclear content)\",\n      \"pmids\": [\"9488724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CK2 phosphorylates α-synuclein constitutively at serine 129 in vivo. This phosphorylation site was mapped by site-directed mutagenesis and confirmed by in vitro kinase assay and two-dimensional phosphopeptide mapping. Inhibition of CK2 in vivo reduces phosphorylation at Ser129.\",\n      \"method\": \"Site-directed mutagenesis, in vitro kinase assay, 2D phosphopeptide mapping, CK2 inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with mutagenesis and in vivo pharmacological validation\",\n      \"pmids\": [\"10617630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CK2 phosphorylates the tumor suppressor PTEN at a cluster of Ser/Thr residues in its C-terminal regulatory domain in a constitutive manner. Phosphorylation-defective PTEN mutants showed decreased stability and accelerated proteasomal degradation, indicating that CK2-mediated phosphorylation stabilizes PTEN against proteasomal degradation.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, proteasome inhibitor studies, protein stability assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with mutagenesis and functional stability readout\",\n      \"pmids\": [\"11035045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CK2 directly phosphorylates p62/SQSTM1 at serine 403 within its ubiquitin-associated (UBA) domain. This phosphorylation increases the affinity of UBA for polyubiquitin chains, enhancing autophagic clearance of polyubiquitinated proteins. CK2 overexpression reduces formation of polyglutamine-expanded huntingtin inclusion bodies in a p62-dependent manner.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, autophagy flux assays, cellular inclusion body formation assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro phosphorylation with mutagenesis and multiple functional readouts\",\n      \"pmids\": [\"22017874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Yeast Cka2 kinase phosphorylates C-terminal serines of the E2 ubiquitin-conjugating enzyme Cdc34 (tmCdc34 mutant), and this phosphorylation prevents the synthesis of free polyubiquitin chains, likely by promoting their attachment to substrate. This reveals a regulatory role for CK2α in the ubiquitin-proteasome pathway.\",\n      \"method\": \"In vitro kinase assay, polyubiquitination assay, genetic epistasis with Ubp14\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro kinase assay with defined functional consequence, single study\",\n      \"pmids\": [\"21453497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Yeast CKA2 regulates nitric oxide (NO) accumulation by controlling NOS-like activity, and thereby functions in H2O2-induced apoptosis and high-temperature stress tolerance. Δcka2 mutants show reduced NO accumulation, decreased NOS-like activity, reduced apoptosis after H2O2, and hypersensitivity to high temperature.\",\n      \"method\": \"Gene deletion, NO measurement, NOS-like activity assay, survival assay with NO donor rescue\",\n      \"journal\": \"FEMS yeast research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion with pharmacological rescue, multiple stress phenotypes\",\n      \"pmids\": [\"26100262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CSNK2A1 (CK2α) physically binds to and phosphorylates SIRT6. Evidence includes co-immunoprecipitation, GST pull-down assay, in vitro kinase assay, and transfection of kinase-dead CSNK2A1. CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 promotes breast cancer cell proliferation and invasion; mutation of Ser338 inhibits MCF7 proliferation and decreases expression of MMP9, β-catenin, cyclin D1, and NF-κB.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, in vitro kinase assay, site-directed mutagenesis, knockdown/overexpression with proliferation/invasion readouts\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (Co-IP, pulldown, in vitro kinase, mutagenesis) in single study\",\n      \"pmids\": [\"27746184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"De novo missense and canonical splice site mutations in CSNK2A1 cause a human neurodevelopmental syndrome (Okur-Chung syndrome) characterized by intellectual disability, developmental delay, hypotonia, speech problems, microcephaly, and dysmorphic features. This is the first report of germline CSNK2A1 mutations causing human disease.\",\n      \"method\": \"Whole exome sequencing of 4102 intellectual disability/developmental delay cases, identification of de novo variants\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large-scale WES with multiple independent de novo variants, defining new disease gene\",\n      \"pmids\": [\"27048600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CSNK2A1 promotes gastric cancer invasion through the PI3K-Akt-mTOR signaling pathway and facilitates epithelial-mesenchymal transition (EMT). Overexpression of CSNK2A1 increases proliferation, invasion, and migration; silencing inhibits these processes. Western blot confirmed modulation of PI3K-Akt-mTOR pathway components.\",\n      \"method\": \"Stable overexpression and knockdown cell lines, invasion/migration assays, Western blot for pathway components\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — KD/OE with pathway readout but no direct biochemical mechanism established\",\n      \"pmids\": [\"31819646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The crystal structures of Cryptococcus neoformans CK2α ortholog (Cka1) in complex with AMPPNP-Mg2+ (2.40 Å) and CX-4945 inhibitor (2.09 Å) were solved. Structural comparison reveals dynamic architecture of the N-lobe across species. In vitro kinase assay demonstrated that CX-4945 inhibits human CK2α more efficiently than Cka1, explaining differences in binding affinity.\",\n      \"method\": \"X-ray crystallography, in vitro kinase inhibition assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional inhibition validation\",\n      \"pmids\": [\"31591414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-1184 directly targets CSNK2A1 mRNA as validated by RNA immunoprecipitation and luciferase reporter assay. Overexpression of miR-1184 suppresses colon cancer cell proliferation and promotes apoptosis, effects reversed by CSNK2A1 overexpression, placing CSNK2A1 downstream of miR-1184 in this pathway.\",\n      \"method\": \"Luciferase reporter assay, RNA immunoprecipitation, overexpression/knockdown with functional rescue\",\n      \"journal\": \"Molecular and cellular probes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct target validation by two methods with functional rescue\",\n      \"pmids\": [\"32619668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A novel chromosomal fusion gene CSNK2A1-PDGFRB was identified in myeloid neoplasm with eosinophilia. The fusion retains the entire kinase domain of PDGFRB and responds to imatinib at low concentration, resulting in sustained complete remission.\",\n      \"method\": \"RNA sequencing, RT-PCR, Sanger sequencing, clinical imatinib treatment response\",\n      \"journal\": \"Cancer research and treatment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — fusion gene characterized by multiple molecular methods with clinical functional consequence\",\n      \"pmids\": [\"33421986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2A1-mediated phosphorylation of SIRT6 at Ser338 activates the DNA damage repair pathway, conferring resistance to doxorubicin in osteosarcoma cells. Overexpression of CSNK2A1 induces resistance; knockdown potentiates cytotoxicity. In vivo, mutation of SIRT6 Ser338 attenuates CSNK2A1-mediated resistance. The CK2 inhibitor emodin potentiated doxorubicin cytotoxicity.\",\n      \"method\": \"Overexpression/knockdown, site-directed mutagenesis of phosphorylation site, in vivo xenograft model, pharmacological inhibition\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of specific phosphorylation site with in vitro and in vivo validation\",\n      \"pmids\": [\"34359939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CSNK2A1 binds to and phosphorylates HMGA2. LC-MS/MS identified high-potential HMGA2-CSNK2A1 interaction; immunoprecipitation confirmed binding; immunofluorescence showed co-localization in the nucleus. Cisplatin induces CSNK2A1-HMGA2 interaction and promotes HMGA2 phosphorylation; CX-4945 (CSNK2A1 inhibitor) blocks HMGA2 phosphorylation and sensitizes tumor cells to cisplatin.\",\n      \"method\": \"LC-MS/MS, co-immunoprecipitation, immunofluorescence, pharmacological inhibition with CX-4945\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified interaction confirmed by Co-IP and pharmacological validation\",\n      \"pmids\": [\"34115920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The fission yeast CK2 catalytic subunit Cka1 phosphorylates the transcriptional coactivator PC4 at two serine residues, downregulating its RNA polymerase II coactivator function. The regulatory β-subunit (Ckb1) downregulates PC4 phosphorylation by Cka1. Mutation of both serine residues abolishes CK2 phosphorylation and the phosphorylation-insensitive mutant retains transcriptional coactivator activity even after Cka1 treatment.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, in vitro transcription assay\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with mutagenesis and functional transcription assay\",\n      \"pmids\": [\"36012759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Skeletal muscle-specific conditional knockout of CSNK2A1 in mice causes age-dependent reduced grip strength, impaired neuromuscular transmission, fragmented neuromuscular junctions (NMJs) with increased synaptic gene expression, increased central nuclei (muscle regeneration marker), impaired oxidative metabolism, and stimulated autophagy. Loss of CSNK2A1 also alters protein abundance of other CK2 subunits.\",\n      \"method\": \"Conditional knockout mouse (HSA-Cre), grip strength testing, electrophysiology, immunohistochemistry, enzyme activity assays, Western blot\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with multiple orthogonal readouts across muscle biology\",\n      \"pmids\": [\"36552726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CircNDST1 binds CSNK2A1 protein directly (RNA pull-down and RIP validated) and promotes interaction between CSNK2A1 and AKT, leading to activation of the PI3K-Akt pathway and EMT in papillary thyroid cancer. Acting as a scaffold, circNDST1 enhances CSNK2A1-AKT physical association.\",\n      \"method\": \"RNA pull-down, RNA immunoprecipitation, Western blot for pathway activation, knockdown studies\",\n      \"journal\": \"Journal of endocrinological investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RNA-protein binding validated by two methods with functional pathway consequence\",\n      \"pmids\": [\"36306106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CSNK2A1-mediated phosphorylation of MAX shifts MAX from MAX-MAX homodimers to C-MYC-MAX and β-catenin-MAX heterodimers, increasing HMGB1 and IL-6 promoter activities. Overexpression of phosphorylated MAX promotes cell proliferation, migration, invasion, and cholangiocarcinogenesis; CX-4945 (CK2 inhibitor) reverses these effects.\",\n      \"method\": \"Co-immunoprecipitation, promoter activity assays, overexpression/knockdown, CX-4945 pharmacological inhibition, in vivo mouse model\",\n      \"journal\": \"Hepatology communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with promoter activity and functional rescue by CK2 inhibitor\",\n      \"pmids\": [\"37347224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DUSP2 competes with AKT1 to bind CSNK2A1, thereby inhibiting CSNK2A1-mediated phosphorylation of AKT1 and promoting apoptosis in pancreatic cancer. Aberrant AKT1 activation leads to TRIM21-mediated ubiquitination and proteasomal degradation of DUSP2, forming a positive feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, competitive binding assay, phosphorylation analysis, in vitro and in vivo apoptosis assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP demonstrating competition, with in vitro and in vivo functional validation\",\n      \"pmids\": [\"37390887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TMPO-AS1L lncRNA acts as a scaffold that strengthens the interaction between CSNK2A1 and DDX3X, activating Wnt/β-catenin signaling to promote prostate cancer bone metastasis.\",\n      \"method\": \"Co-immunoprecipitation, RNA pulldown, in vitro and in vivo functional assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scaffold mechanism validated by Co-IP and RNA pulldown\",\n      \"pmids\": [\"37542040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CSNK2A1 confers gemcitabine resistance in pancreatic ductal adenocarcinoma by activating autophagy. CSNK2A1 transcription is regulated by H3K27 acetylation. Silmitasertib (CSNK2A1 inhibitor) effectively inhibits autophagy and, in combination with gemcitabine, shows remarkable efficacy in PDAC patient-derived xenograft models.\",\n      \"method\": \"Bioinformatics, PDX model, siRNA knockdown, Silmitasertib pharmacological inhibition, autophagy assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — PDX model with pharmacological inhibition and mechanistic pathway analysis\",\n      \"pmids\": [\"38290659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OGT promotes O-GlcNAc glycosylation of CSNK2A1, enhancing its protein stability. OGT-mediated glycosylation of CSNK2A1 reverses tumor suppression caused by CSNK2A1 knockdown, and CSNK2A1 promotes colorectal cancer progression via the PI3K/AKT pathway.\",\n      \"method\": \"Immunoprecipitation, Western blot, immunofluorescence for O-GlcNAc modification, knockdown rescue assay, tumor-bearing mouse model\",\n      \"journal\": \"Molecular biotechnology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — PTM validated by IP with functional rescue, in vivo model\",\n      \"pmids\": [\"38289573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cholesterol directly binds CSNK2A1 and augments its kinase activity, leading to phosphorylation of IGF2R at Ser2484. This cascade rewires lipid-driven mitochondrial oxidative phosphorylation and creates a positive feedback loop for cholesterol biosynthesis in hepatocellular carcinoma. Initial transcriptional activation of CSNK2A1 is driven by RAD21 upregulation.\",\n      \"method\": \"Proteomics, phosphoproteomics, cholesterol-binding assay, in vitro kinase assay, patient-derived organoids and xenografts\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay combined with in vitro kinase assay, phosphoproteomics, and in vivo validation\",\n      \"pmids\": [\"39547439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SOX4 transcription factor upregulates CSNK2A1 expression by binding to its promoter (confirmed by ChIP and dual-luciferase reporter). Elevated CSNK2A1 phosphorylates TOP2A, promoting breast cancer cell proliferation, migration, invasion, and tumor growth in vivo. Silencing SOX4 reduces CSNK2A1-TOP2A phosphorylation and suppresses tumor growth.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, RT-qPCR, Western blot, CCK-8, colony formation, Transwell assay, mouse xenograft model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-confirmed transcriptional regulation with in vitro and in vivo functional validation\",\n      \"pmids\": [\"39931818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"S. pombe Cka1 (CK2α ortholog) interacts with components of the RSC chromatin remodeling complex, DNA packaging complexes, the Pcs1/Mde4 monopolin complex, and snoRNA-containing ribonucleoproteins and spliceosomal machinery. In vitro kinase assays confirmed that Cka1 directly phosphorylates Pcs1 and Mde4, monopolin subunits involved in mitotic division.\",\n      \"method\": \"RNase-free tandem affinity purification coupled with mass spectrometry, in vitro kinase assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — AP-MS interaction screen validated by direct in vitro kinase assay for specific substrates\",\n      \"pmids\": [\"40700808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A frameshift mutation in CSNK2A1 (c.1020_1021delAG, p.Gly342Glnfs*57) significantly reduces protein expression through elevated ubiquitination-dependent proteasomal degradation, despite elevated mutant mRNA levels. In vitro kinase assay showed the variant did not impair intrinsic kinase activity, indicating the pathogenic mechanism is reduced protein abundance rather than catalytic dysfunction.\",\n      \"method\": \"In vitro kinase assay, quantitative mRNA/protein analysis, ubiquitination assay, bioinformatic structural prediction\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro kinase assay with protein stability and ubiquitination functional analysis\",\n      \"pmids\": [\"41216289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CSNK2A1 modulates dermal fibroblast senescence; ellagic acid upregulates CSNK2A1 expression, activates Nrf2, reduces ROS and inflammatory cytokines (IL-6, TNF-α, IL-1β) via NF-κB p65 inhibition. Silmitasertib (CSNK2A1 inhibitor) negates these anti-senescence effects, demonstrating CSNK2A1's role in oxidative stress and inflammation signaling.\",\n      \"method\": \"MTT assay, Western blot, fluorescence ROS staining, SA-β-gal staining, flow cytometry, TUNEL assay, pharmacological inhibition\",\n      \"journal\": \"Clinical, cosmetic and investigational dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibition with multiple senescence readouts, mechanism inferred\",\n      \"pmids\": [\"40860313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CK2 inhibitor CX-4945 decreases EWS-FLI1 oncoprotein abundance in Ewing sarcoma cells through increased ubiquitination and proteasomal degradation. Genetic inhibition of CK2 recapitulates this effect, demonstrating CSNK2A1-dependent stabilization of EWS-FLI1. CX-4945 shows anti-tumor activity in metastatic xenograft models and synergistic cytotoxicity with temozolomide and irinotecan.\",\n      \"method\": \"Genetic knockdown, pharmacological inhibition (CX-4945), ubiquitination assay, tumor organoids, patient-derived xenograft cells, in vivo xenograft model\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological concordance with mechanistic ubiquitination readout, preprint\",\n      \"pmids\": [\"bio_10.1101_2025.09.24.677357\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"CSNK2A1 encodes the catalytic α subunit of the constitutively active, ubiquitous serine/threonine kinase CK2, which forms an α2β2 tetrameric holoenzyme and phosphorylates over 100 substrates including SIRT6 (Ser338), PTEN (C-terminal cluster), α-synuclein (Ser129), p62/SQSTM1 (Ser403), HMGA2, MAX, TOP2A, AKT1, IGF2R (Ser2484), and Pcs1/Mde4; it localizes to both nucleus and cytoplasm, is essential for viability in yeast (via roles in cell polarity and the actin cytoskeleton), regulates autophagy, DNA damage repair, Wnt/β-catenin and PI3K-AKT-mTOR signaling, and protein stability (PTEN, EWS-FLI1); its stability is enhanced by OGT-mediated O-GlcNAcylation; cholesterol directly binds and activates it; and germline loss-of-function mutations cause Okur-Chung neurodevelopmental syndrome.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CSNK2A1 encodes the alpha catalytic subunit of protein kinase CK2, a constitutively active serine/threonine kinase that functions both as a free catalytic monomer and within an alpha2-beta2 holoenzyme and is essential for cell viability [PMID:2196445, PMID:1527008]. The kinase phosphorylates a broad spectrum of substrates—including SIRT6 (Ser338), AKT1, HMGA2, MAX, TOP2A, PC4, and IGF2R (Ser2484)—thereby regulating DNA damage repair, Wnt/β-catenin signaling, PI3K-AKT-mTOR signaling, autophagy, transcription, and ubiquitin-conjugation specificity [PMID:27746184, PMID:37390887, PMID:37347224, PMID:39931818, PMID:36012759, PMID:39547439, PMID:21453497]. CSNK2A1 activity is modulated by cholesterol binding, O-GlcNAcylation-dependent protein stabilization, and epigenetic/transcriptional inputs including H3K27 acetylation and SOX4-driven promoter activation [PMID:39547439, PMID:38289573, PMID:37391010, PMID:39931818]. In vivo, muscle-specific CSNK2A1 knockout causes progressive neuromuscular junction fragmentation, impaired oxidative metabolism, and stimulated autophagy, while in yeast the orthologous subunit is specifically required for cell polarity and actin cytoskeleton organization [PMID:36552726, PMID:9488724].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing that CK2 possesses two distinct catalytic subunits resolved a longstanding ambiguity about holoenzyme composition and revealed genetic redundancy between CKA1 and CKA2.\",\n      \"evidence\": \"Gene disruption and biochemical fractionation in S. cerevisiae\",\n      \"pmids\": [\"3062376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the two catalytic subunits have distinct substrate specificities was not addressed\",\n        \"Mammalian orthologue function not yet tested\"\n      ]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that simultaneous loss of both catalytic subunits is lethal—and that a Drosophila alpha subunit rescues viability—established CK2 catalytic activity as an essential, evolutionarily conserved cellular function.\",\n      \"evidence\": \"Double gene disruption in yeast with cross-species complementation\",\n      \"pmids\": [\"2196445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Essential substrates mediating lethality were unknown\",\n        \"Whether essential function maps to holoenzyme or free subunit was unresolved\"\n      ]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Purification of the alpha2-beta2 tetramer and demonstration that the free alpha monomer retains catalytic activity resolved the question of whether beta subunits are required for phosphotransfer.\",\n      \"evidence\": \"Biochemical purification and in vitro kinase assay from yeast\",\n      \"pmids\": [\"1527008\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo substrates specific to free alpha versus holoenzyme were not distinguished\",\n        \"Structural basis for constitutive activity unknown\"\n      ]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Temperature-sensitive CKA1 alleles revealed a specific requirement for this catalytic subunit in actin polarization and cell polarity, demonstrating functional specialization between CKA1 and CKA2 beyond simple redundancy.\",\n      \"evidence\": \"Conditional alleles in yeast with actin/chitin staining and cell morphology analysis\",\n      \"pmids\": [\"9488724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct polarity substrates of CKA1 were not identified\",\n        \"Whether mammalian CSNK2A1 has analogous polarity functions was unknown\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing that CK2-mediated phosphorylation of the E2 enzyme Cdc34 redirects ubiquitin chain assembly from free chains to substrate-attached chains established a mechanism by which CK2 controls ubiquitination specificity.\",\n      \"evidence\": \"In vitro ubiquitination assays and yeast genetic epistasis (ubp14/cka2 mutants)\",\n      \"pmids\": [\"21453497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether this regulatory mechanism operates in mammalian cells was not tested\",\n        \"Identity of physiological ubiquitination substrates affected was not determined\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of SIRT6 Ser338 as a direct CSNK2A1 phosphorylation site linked CK2 activity to a specific signaling output—β-catenin/NF-κB–driven proliferation—in a mammalian disease context.\",\n      \"evidence\": \"Co-IP, GST pull-down, in vitro kinase assay, and Ser338 mutagenesis in breast cancer cells\",\n      \"pmids\": [\"27746184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether SIRT6 phosphorylation operates in non-cancer tissues was unknown\",\n        \"Structural basis of the CSNK2A1-SIRT6 interaction was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstration that miR-1184 directly targets the CSNK2A1 3′UTR established a post-transcriptional regulatory input controlling CK2 abundance in colon cancer.\",\n      \"evidence\": \"Luciferase 3′UTR reporter and RNA immunoprecipitation with functional rescue\",\n      \"pmids\": [\"32619668\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological relevance of miR-1184 regulation in normal tissue was not assessed\",\n        \"Whether additional miRNAs converge on CSNK2A1 was unexplored\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extension of the SIRT6-Ser338 axis to DNA damage repair and doxorubicin resistance, together with identification of HMGA2 as a cisplatin-induced CSNK2A1 substrate, broadened the mechanistic link between CK2 and chemoresistance across cancer types.\",\n      \"evidence\": \"Ser338 mutagenesis with xenograft validation (osteosarcoma); LC-MS/MS interaction screen and CX-4945 inhibitor studies (cervical cancer)\",\n      \"pmids\": [\"34359939\", \"34115920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"HMGA2 phosphorylation site(s) were not mapped\",\n        \"Whether SIRT6 and HMGA2 axes operate in the same or distinct resistance programs was not tested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Muscle-specific CSNK2A1 knockout in mice established the first mammalian tissue-specific requirement, showing that CK2α is necessary for neuromuscular junction integrity, oxidative metabolism, and suppression of autophagy in skeletal muscle.\",\n      \"evidence\": \"Conditional knockout mouse (HSA-Cre) with electromyography, histology, and molecular analysis\",\n      \"pmids\": [\"36552726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct phosphorylation targets mediating NMJ fragmentation were not identified\",\n        \"Contribution of compensatory CK2α′ upregulation was not fully dissected\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Reconstitution of CK2-mediated PC4 phosphorylation in a fission yeast transcription system demonstrated that the free catalytic subunit suppresses RNA Pol II coactivator function, while the beta regulatory subunit antagonizes this activity, defining a CK2 subunit-composition-dependent transcriptional switch.\",\n      \"evidence\": \"In vitro kinase and transcription assays with recombinant CK2 subunits and PC4 serine mutants\",\n      \"pmids\": [\"36012759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether this regulatory logic applies to mammalian PC4 homologues was not tested\",\n        \"In vivo transcriptomic consequences were not measured\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multiple studies converged on CSNK2A1 as a central node whose substrate choice is modulated by scaffolding RNAs and competing binding partners: circNDST1 and lncRNA TMPO-AS1L direct CSNK2A1 toward AKT and DDX3X/β-catenin, respectively, while DUSP2 competitively blocks AKT phosphorylation, establishing RNA- and protein-mediated substrate-selection mechanisms.\",\n      \"evidence\": \"RNA pull-down, RIP, reciprocal Co-IP, competition binding assays, and in vivo xenograft models across thyroid, prostate, and pancreatic cancer\",\n      \"pmids\": [\"36306106\", \"37542040\", \"37390887\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural basis for RNA-mediated scaffolding of CSNK2A1 is unknown\",\n        \"Whether these RNA scaffolds compete with each other for CSNK2A1 binding was not examined\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of MAX as a CSNK2A1 substrate that shifts MYC-MAX versus MAX-MAX dimer equilibrium connected CK2 to MYC-dependent transcription and inflammatory gene activation in cholangiocarcinoma.\",\n      \"evidence\": \"Overexpression/silencing, luciferase promoter reporters for HMGB1/IL-6, protein half-life assays, CX-4945 inhibitor rescue\",\n      \"pmids\": [\"37347224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific MAX phosphorylation site(s) were not mapped by mass spectrometry\",\n        \"Whether MAX phosphorylation alters genome-wide MYC target gene programs was not assessed\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"ChIP-based demonstration that P300-deposited H3K27ac at the CSNK2A1 promoter drives its overexpression in colorectal cancer, activating PI3K-AKT-mTOR and EMT, established an epigenetic input controlling CK2 abundance in cancer.\",\n      \"evidence\": \"ChIP for H3K27ac, CSNK2A1 knockdown/overexpression, PI3K inhibitor rescue in colorectal cancer cells\",\n      \"pmids\": [\"37391010\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether H3K27ac-driven upregulation is cancer-specific or occurs in normal tissue was not determined\",\n        \"Identity of the upstream signal activating P300 at this locus was not identified\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that cholesterol directly binds and activates CSNK2A1, leading to IGF2R Ser2484 phosphorylation and a ROS-driven positive feedback loop for cholesterol biosynthesis, revealed a metabolite-sensing function for CK2α beyond classical constitutive activity.\",\n      \"evidence\": \"Phosphoproteomics, cholesterol binding assay, in vitro kinase assay, patient-derived organoids and xenografts\",\n      \"pmids\": [\"39547439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Binding site for cholesterol on CSNK2A1 was not structurally resolved\",\n        \"Whether other lipids similarly activate CK2α was not tested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstration that OGT-mediated O-GlcNAcylation stabilizes CSNK2A1 protein and that a disease-associated frameshift increases CSNK2A1 ubiquitination and degradation established post-translational regulation of CK2α abundance as a functional control point.\",\n      \"evidence\": \"Immunoprecipitation for O-GlcNAc, ubiquitination assays, in vitro kinase assay comparing wild-type and frameshift mutant\",\n      \"pmids\": [\"38289573\", \"41216289\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"O-GlcNAcylation site(s) on CSNK2A1 were not mapped\",\n        \"Whether O-GlcNAcylation and ubiquitination compete at the same or proximal residues is unknown\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of SOX4 as a direct transcriptional activator of CSNK2A1 and TOP2A as a downstream phosphorylation substrate added a transcription-factor-to-kinase-to-substrate axis driving breast cancer proliferation.\",\n      \"evidence\": \"ChIP and dual-luciferase reporter for CSNK2A1 promoter, TOP2A phosphorylation assays, SOX4 silencing in vitro and in vivo\",\n      \"pmids\": [\"39931818\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"TOP2A phosphorylation site targeted by CK2α was not mapped\",\n        \"Whether SOX4-driven CK2α upregulation is specific to breast cancer or generalizable was not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for cholesterol activation, the full catalogue of context-dependent substrates in normal versus cancer tissues, the interplay between O-GlcNAcylation and ubiquitination in controlling CK2α turnover, and whether RNA scaffold-mediated substrate selection operates in non-cancer physiology.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of cholesterol-bound or O-GlcNAcylated CSNK2A1 exists\",\n        \"Systematic substrate profiling across normal tissues has not been performed\",\n        \"Physiological relevance of RNA-scaffolded substrate targeting is untested outside cancer\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 4, 5, 6, 7, 8, 11, 15, 17, 19]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 4, 5, 6, 7, 11, 15, 17, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [8, 9, 10, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 9, 10, 16]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 15, 19]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [12, 14, 17]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [\n      \"CK2 holoenzyme (alpha2-beta2 tetramer)\"\n    ],\n    \"partners\": [\n      \"CSNK2B\",\n      \"SIRT6\",\n      \"AKT1\",\n      \"MAX\",\n      \"DDX3X\",\n      \"HMGA2\",\n      \"DUSP2\",\n      \"OGT\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CSNK2A1 encodes the catalytic α subunit of casein kinase II (CK2), a constitutively active, ubiquitous serine/threonine kinase that assembles into an α2β2 tetrameric holoenzyme and phosphorylates more than 100 substrates to regulate cell division, signal transduction, protein stability, autophagy, and DNA damage repair [PMID:7896000, PMID:22017874, PMID:34359939]. CK2α is essential for viability—demonstrated by lethality of dual catalytic-subunit deletion in yeast—and functions in cell polarity and actin cytoskeleton organization; in mouse skeletal muscle, conditional loss causes neuromuscular junction fragmentation, impaired oxidative metabolism, and stimulated autophagy [PMID:2196445, PMID:9488724, PMID:36552726]. Key substrates include PTEN (C-terminal phosphorylation stabilizing the protein against proteasomal degradation), α-synuclein (Ser129), p62/SQSTM1 (Ser403, enhancing autophagic clearance), SIRT6 (Ser338, activating DNA damage repair), AKT1, MAX, and IGF2R (Ser2484), with CK2α activity itself modulated by cholesterol binding and OGT-mediated O-GlcNAcylation [PMID:11035045, PMID:10617630, PMID:22017874, PMID:27746184, PMID:39547439, PMID:38289573]. Germline loss-of-function mutations in CSNK2A1 cause Okur-Chung neurodevelopmental syndrome [PMID:27048600].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Identification of the yeast CKA1 gene as encoding the CK2 catalytic α subunit established genetic access to CK2 and revealed functional redundancy with CKA2.\",\n      \"evidence\": \"Gene isolation, sequencing, and gene disruption in S. cerevisiae\",\n      \"pmids\": [\"3062376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional specialization between α and α′ not yet resolved\", \"No mammalian ortholog characterization\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that simultaneous loss of both catalytic subunits is lethal—rescued by Drosophila CK2α—established CK2 as an essential, evolutionarily conserved kinase.\",\n      \"evidence\": \"Double gene disruption and cross-species complementation in yeast\",\n      \"pmids\": [\"2196445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Essential substrates not identified\", \"Requirement for β subunit in vivo unclear\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Purification of catalytically active free CK2α monomer from rescued yeast showed that the β subunit is dispensable for basal catalytic activity, defining CK2α as an autonomous kinase.\",\n      \"evidence\": \"Biochemical purification and in vitro kinase assays from genetically rescued strains\",\n      \"pmids\": [\"1527008\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate specificity differences between free α and holoenzyme not resolved\", \"In vivo relevance of monomeric activity uncertain\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Temperature-sensitive CKA1 alleles revealed a specific role in cell polarity maintenance, with actin delocalization and multinucleate arrest, distinguishing CKA1 from CKA2 function.\",\n      \"evidence\": \"Conditional allele with fluorescence microscopy and cell cycle analysis in yeast\",\n      \"pmids\": [\"9488724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct polarity substrates not identified\", \"Mechanism linking CK2α to actin organization unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of α-synuclein Ser129 as a constitutive CK2 phosphorylation site in vivo provided the first link between CK2 and neurodegeneration-associated substrates.\",\n      \"evidence\": \"Site-directed mutagenesis, in vitro kinase assay, 2D phosphopeptide mapping, and CK2 inhibitor treatment in cells\",\n      \"pmids\": [\"10617630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Ser129 phosphorylation on α-synuclein aggregation not determined in this study\", \"Whether CK2 is the sole Ser129 kinase in vivo unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that CK2-mediated C-terminal phosphorylation of PTEN protects it from proteasomal degradation established CK2 as a regulator of tumor suppressor stability.\",\n      \"evidence\": \"In vitro kinase assay, phosphorylation-defective PTEN mutants, proteasome inhibitor and stability assays\",\n      \"pmids\": [\"11035045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the E3 ligase targeting unphosphorylated PTEN not identified\", \"In vivo relevance in tumor models not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CK2 phosphorylation of p62/SQSTM1 at Ser403 enhanced UBA domain affinity for polyubiquitin chains and autophagic clearance, directly linking CK2 to selective autophagy.\",\n      \"evidence\": \"In vitro kinase assay, mutagenesis, autophagy flux assays, and polyglutamine inclusion body assay\",\n      \"pmids\": [\"22017874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CK2 regulates autophagy through additional substrates beyond p62 not addressed\", \"Tissue-specific relevance not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery that de novo CSNK2A1 mutations cause Okur-Chung neurodevelopmental syndrome established the first Mendelian disease link and confirmed the gene's essential role in human brain development.\",\n      \"evidence\": \"Whole exome sequencing of 4102 intellectual disability cases with identification of multiple independent de novo variants\",\n      \"pmids\": [\"27048600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pathogenic mechanism (loss of kinase activity vs. dominant-negative vs. haploinsufficiency) not resolved\", \"No functional assays on patient variants reported in this study\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CK2α was shown to phosphorylate SIRT6 at Ser338, with downstream effects on β-catenin and NF-κB signaling in breast cancer, establishing SIRT6 as a functionally consequential CK2 substrate.\",\n      \"evidence\": \"Co-IP, GST pull-down, in vitro kinase assay, and site-directed mutagenesis with proliferation and invasion readouts\",\n      \"pmids\": [\"27746184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SIRT6 phosphorylation affects its deacetylase activity directly not measured\", \"Generalizability beyond breast cancer not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extending the SIRT6 axis, CK2α-mediated Ser338 phosphorylation was shown to activate DNA damage repair and confer doxorubicin resistance in osteosarcoma, broadening CK2's role to chemoresistance.\",\n      \"evidence\": \"Site-directed mutagenesis, in vivo xenograft model, pharmacological inhibition with emodin\",\n      \"pmids\": [\"34359939\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific DNA repair pathway is activated not delineated\", \"Whether other CK2 substrates contribute to chemoresistance in parallel not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Muscle-specific Csnk2a1 knockout mice revealed age-dependent neuromuscular junction fragmentation, impaired oxidative metabolism, and stimulated autophagy, establishing CK2α as essential for mammalian skeletal muscle homeostasis.\",\n      \"evidence\": \"Conditional knockout (HSA-Cre), grip strength, electrophysiology, immunohistochemistry, and enzyme activity assays\",\n      \"pmids\": [\"36552726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation substrates mediating NMJ maintenance not identified\", \"Whether neuronal CK2α contributes to the phenotype not distinguished\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CK2α phosphorylation of MAX was shown to shift MAX from homodimers to C-MYC–MAX and β-catenin–MAX heterodimers, activating HMGB1/IL-6 transcription, revealing a mechanism by which CK2 modulates MYC-dependent gene expression.\",\n      \"evidence\": \"Co-IP, promoter activity assays, CX-4945 inhibition, in vivo mouse model\",\n      \"pmids\": [\"37347224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific phosphorylation site(s) on MAX not mapped in this study\", \"Whether this mechanism operates in non-malignant contexts unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cholesterol was identified as a direct CK2α-binding ligand that augments kinase activity and drives phosphorylation of IGF2R at Ser2484, creating a metabolic feedback loop coupling lipid sensing to mitochondrial oxidative phosphorylation.\",\n      \"evidence\": \"Cholesterol-binding assay, in vitro kinase assay, phosphoproteomics, patient-derived organoids and xenografts\",\n      \"pmids\": [\"39547439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of cholesterol–CK2α binding not resolved\", \"Whether other lipids also modulate CK2 activity not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"OGT-mediated O-GlcNAcylation of CK2α was shown to enhance its protein stability, identifying a post-translational mechanism that tunes CK2 abundance in colorectal cancer.\",\n      \"evidence\": \"Immunoprecipitation for O-GlcNAc modification, knockdown rescue, tumor-bearing mouse model\",\n      \"pmids\": [\"38289573\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific O-GlcNAcylation sites on CK2α not mapped\", \"Whether O-GlcNAcylation affects kinase activity independently of stability not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A pathogenic frameshift variant in CSNK2A1 was shown to reduce protein abundance through elevated ubiquitination-dependent degradation rather than impairing catalytic activity, clarifying a loss-of-function mechanism in Okur-Chung syndrome.\",\n      \"evidence\": \"In vitro kinase assay, quantitative mRNA/protein analysis, ubiquitination assay\",\n      \"pmids\": [\"41216289\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single variant studied; generalizability to other OCNDS variants unknown\", \"No neuronal or brain-relevant model used\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"AP-MS of fission yeast Cka1 revealed interactions with RSC chromatin remodeling, monopolin, and spliceosomal complexes, with direct phosphorylation of monopolin subunits Pcs1 and Mde4 expanding CK2's role to chromosome segregation.\",\n      \"evidence\": \"RNase-free tandem affinity purification with mass spectrometry, in vitro kinase assay\",\n      \"pmids\": [\"40700808\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of monopolin phosphorylation on chromosome segregation fidelity not tested\", \"Validation in mammalian systems absent\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for allosteric activation of CK2α by cholesterol and other ligands, the complete inventory of CK2α substrates that mediate neurodevelopmental pathology in Okur-Chung syndrome, and whether monomeric versus holoenzyme CK2α pools have distinct substrate selectivity in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of cholesterol–CK2α complex\", \"Neuronal substrates relevant to OCNDS not identified\", \"In vivo partitioning between monomeric and holoenzyme CK2α activity not measured\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 4, 7, 8, 9, 12, 15, 20, 24, 28, 29, 30]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [7, 8, 9, 12, 20, 24, 28, 29, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 14, 22, 23, 24, 25, 28]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [9, 21, 26]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 6, 30]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 10, 27, 31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 14, 17, 23, 26, 29]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 24]}\n    ],\n    \"complexes\": [\n      \"CK2 holoenzyme (α2β2 tetramer)\"\n    ],\n    \"partners\": [\n      \"CSNK2B\",\n      \"SIRT6\",\n      \"PTEN\",\n      \"SQSTM1\",\n      \"AKT1\",\n      \"HMGA2\",\n      \"MAX\",\n      \"DDX3X\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}